Sort   by:  
 Page size 
UnknownAlterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
Not available
S-EPMC9425187 | biostudies-literature
UnknownCheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Not available
S-EPMC6161834 | biostudies-literature
UnknownA genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer.
Not available
S-EPMC8096820 | biostudies-literature
UnknownGenomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
Not available
S-EPMC5894850 | biostudies-literature
UnknownIncidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain.
Not available
S-EPMC6982555 | biostudies-literature
UnknownDual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Not available
S-EPMC4155006 | biostudies-literature
UnknownOvercoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.
Not available
S-EPMC5384386 | biostudies-literature
UnknownPembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial.
Not available
S-EPMC12514504 | biostudies-literature
ProteomicsHuman Colorectal Cancer LC-MS/MS
Suppression of HER2 ADC Internalization and Efficacy by EGFR
ORGANISM(S): Homo sapiens (Human) 
2024-09-17 | PXD052260 | Pride
Human Crc Lc-ms/ms 
UnknownPost-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma.
Not available
S-EPMC5794647 | biostudies-literature
Sort   by:  
 Page size